Cullinan Therapeutics, Inc. (Nasdaq: CGEM) filed a Current Report on Form 8-K on September 24, 2026, outlining specific data presentation milestones for the fourth quarter of 2026. The company intends to share updates across its immunology and oncology pipeline, focusing on its T cell engager portfolio.
In the immunology sector, the company plans to present data for CLN-978, a CD19 T cell engager. Cullinan will share both multi-dose and single target dose regimen data from ongoing Phase 1 clinical trials in patients with treatment-refractory moderate to severe systemic lupus erythematosus (SLE), difficult-to-treat rheumatoid arthritis (RA), and treatment-refractory moderate to severe Sjögren's disease. These data presentations are scheduled for December.
Regarding velinotamig, a BCMA T cell engager, the company will provide multi-dose regimen data from the ongoing Phase 1 dose escalation study in SLE. This data will be shared during a poster session at the American College of Rheumatology Convergence 2026 on November 8, 2026, from 10:30 a.m. to 12:30 p.m. ET.
In oncology, Cullinan plans to share updated data from the dose escalation portion of its Phase 1 trial of CLN-049, an FLT3 T cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML). These updates are also scheduled for December.
